Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive STAR™ research license agreement for the production of monoclonal antibodies and other proteins with Berkeley, California-based XOMA Ltd. (NASDAQ: XOMA). Financial details were not disclosed.